Abstract: Provided are systems and methods of controlling load share in a multi-engine propulsion system. A load share participation value indicative of a load share participation regime for a first engine may be received and a load sharing requirement control command for the first engine may be output. The load share participation value may depend or be based at least in part on one or more operating conditions of a second engine. The load sharing requirement control command for the first engine may depend on whether the load share participation value indicates a full-participation load share regime for the first engine, a partial-participation load share regime for the first engine, or a non-participation load share regime for the first engine.

Abstract: Control schemes for controlling a gas turbine engine in response to disturbances associated with a load mechanically coupled with the gas turbine engine are provided. In one aspect, a gas turbine engine mechanically coupled with a load has a controller that includes executable control logic. The control logic includes a feedforward module, an aggressive control module, and a power turbine governor module. By executing the modules, the controller seeks to maintain a constant power turbine speed stably and subtly in response to small disturbances associated with the load and aggressively in response to large disturbances associated with the load, as well as smooth transitions between the responses.

Abstract: Control schemes for controlling a gas turbine engine in response to disturbances associated with a load mechanically coupled with the gas turbine engine are provided. In one aspect, a gas turbine engine mechanically coupled with a load has a controller that includes executable control logic. The control logic includes a feedforward module, an aggressive control module, and a power turbine governor module. By executing the modules, the controller seeks to maintain a constant power turbine speed stably and subtly in response to small disturbances associated with the load and aggressively in response to large disturbances associated with the load, as well as smooth transitions between the responses.

Abstract: A diffuser-deswirler for a gas turbine engine is provided. The diffuser-deswirler includes an inner shell and an outer shell spaced apart and configured for receiving a flow of compressed air from a compressor of a gas turbine engine. A plurality of vanes extend between the inner shell and the outer shell to define a plurality of fluid passageways and a splitter extends along the circumferential direction between adjacent vanes to split the flow of compressed air passing through the each fluid passageway. All of these components are manufactured as a single monolithic piece and are configured for diffusing and deswirling compressor air before passing it to a combustor for an improved combustion process.

Abstract: A diffuser-deswirler for a gas turbine engine is provided. The diffuser-deswirler includes an inner shell and an outer shell spaced apart and configured for receiving a flow of compressed air from a compressor of a gas turbine engine. A plurality of vanes extend between the inner shell and the outer shell to define a plurality of fluid passageways and a splitter extends along the circumferential direction between adjacent vanes to split the flow of compressed air passing through the each fluid passageway. All of these components are manufactured as a single monolithic piece and are configured for diffusing and deswirling compressor air before passing it to a combustor for an improved combustion process.

Abstract: A diffuser-deswirler for a gas turbine engine is provided. The diffuser-deswirler includes an inner shell and an outer shell spaced apart and configured for receiving a flow of compressed air from a compressor of a gas turbine engine. A plurality of vanes extend between the inner shell and the outer shell to define a plurality of fluid passageways and a splitter extends along the circumferential direction between adjacent vanes to split the flow of compressed air passing through the each fluid passageway. All of these components are manufactured as a single monolithic piece and are configured for diffusing and deswirling compressor air before passing it to a combustor for an improved combustion process.

Abstract: Provided are systems and methods of controlling load share in a multi-engine propulsion system. A load share participation value indicative of a load share participation regime for a first engine may be received and a load sharing requirement control command for the first engine may be output. The load share participation value may depend or be based at least in part on one or more operating conditions of a second engine. The load sharing requirement control command for the first engine may depend on whether the load share participation value indicates a full-participation load share regime for the first engine, a partial-participation load share regime for the first engine, or a non-participation load share regime for the first engine.

Abstract: A diffuser-deswirler for a gas turbine engine is provided. The diffuser-deswirler includes an inner shell and an outer shell spaced apart and configured for receiving a flow of compressed air from a compressor of a gas turbine engine. A plurality of vanes extend between the inner shell and the outer shell to define a plurality of fluid passageways and a splitter extends along the circumferential direction between adjacent vanes to split the flow of compressed air passing through the each fluid passageway. All of these components are manufactured as a single monolithic piece and are configured for diffusing and deswirling compressor air before passing it to a combustor for an improved combustion process.

Abstract: Described herein is the DP2 antagonist 2-(3-(2-((tert-butylthio)methyl)-4-(2,2-dimethyl-propionylamino)phenoxy)-4-methoxyphenyl)acetic acid, or a pharmaceutically acceptable salt thereof. Also described are methods of preparing the DP2 antagonist, or a pharmaceutically acceptable salt thereof. Also described herein are pharmaceutical compositions suitable for administration to a mammal that include the DP2 antagonist, or a pharmaceutically acceptable salt thereof, and methods of using such pharmaceutical compositions for treating respiratory diseases or conditions, allergic diseases or conditions, inflammatory diseases or conditions, as well as other prostaglandin D2-dependent or prostaglandin D2-mediated diseases or conditions.

Abstract: Described herein is the LPA1 antagonist 1-{4?-[3-methyl-4-((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1), or pharmaceutically acceptable salts thereof. Also described are methods of preparing the LPA1 antagonist, or pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions suitable for administration to a mammal that include the LPA1 antagonist, or pharmaceutically acceptable salt thereof, and methods of using such pharmaceutical compositions for treating LPA-dependent or LPA-mediated diseases or conditions.

Abstract: Described herein is the DP2 antagonist [2?-(3-benzyl-1-ethyl-ureidomethyl)-6-methoxy-4?-trifluoromethyl-biphenyl-3-yl]-acetic acid, or a pharmaceutically acceptable salt thereof. Also described are methods of preparing the DP2 antagonist, or a pharmaceutically acceptable salt thereof. Also described herein are pharmaceutical compositions suitable for administration to a mammal that include the DP2 antagonist, or a pharmaceutically acceptable salt thereof, and methods of using such pharmaceutical compositions for treating respiratory diseases or conditions, allergic diseases or conditions, inflammatory diseases or conditions, as well as other prostaglandin D2-dependent or prostaglandin D2-mediated diseases or conditions.

Abstract: Described herein is the LPA1 antagonist 1-{4?-[3-methyl-4-((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1), or pharmaceutically acceptable salts thereof. Also described are methods of preparing the LPA1 antagonist, or pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions suitable for administration to a mammal that include the LPA1 antagonist, or pharmaceutically acceptable salt thereof, and methods of using such pharmaceutical compositions for treating LPA-dependent or LPA-mediated diseases or conditions.

Abstract: Described herein is the DP2 antagonist [2?-(3-benzyl-1-ethyl-ureidomethyl)-6-methoxy-4?-trifluoromethyl-biphenyl-3-yl]-acetic acid, or a pharmaceutically acceptable salt thereof. Also described are methods of preparing the DP2 antagonist, or a pharmaceutically acceptable salt thereof. Also described herein are pharmaceutical compositions suitable for administration to a mammal that include the DP2 antagonist, or a pharmaceutically acceptable salt thereof, and methods of using such pharmaceutical compositions for treating respiratory diseases or conditions, allergic diseases or conditions, inflammatory diseases or conditions, as well as other prostaglandin D2-dependent or prostaglandin D2-mediated diseases or conditions.

Abstract: Described herein is the DP2 antagonist [2?-(3-benzyl-1-ethyl-ureidomethyl)-6-methoxy-4?-trifluoromethyl-biphenyl-3-yl]-acetic acid, or a pharmaceutically acceptable salt thereof. Also described are methods of preparing the DP2 antagonist, or a pharmaceutically acceptable salt thereof. Also described herein are pharmaceutical compositions suitable for administration to a mammal that include the DP2 antagonist, or a pharmaceutically acceptable salt thereof, and methods of using such pharmaceutical compositions for treating respiratory diseases or conditions, allergic diseases or conditions, inflammatory diseases or conditions, as well as other prostaglandin D2-dependent or prostaglandin D2-mediated diseases or conditions.

Abstract: Described herein are methods for the synthesis of 3-[5-(pyridin-2-ylmethoxy)-3-(2-methyl-2-propylthio)-1-[4-(2-methoxypyridin-5-yl)benzyl]-indol-2-yl]-2,2-dimethyl-propionic acid, pharmaceutically acceptable salts, pharmaceutically acceptable solvates thereof. Also described are pharmaceutical compositions suitable for oral administration to a mammal that include, as well as methods of using such oral pharmaceutical compositions for treating respiratory conditions or diseases, as well as other leukotriene-dependent or leukotriene mediated conditions or diseases.

Abstract: Described herein is the LPA1 antagonist 1-{4?-[3-methyl-4-((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-yl]-bi-phenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1), or pharmaceutically acceptable salts thereof. Also described are methods of preparing the LPA1 antagonist, or pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions suitable for administration to a mammal that include the LPA1 antagonist, or pharmaceutically acceptable salt thereof, and methods of using such pharmaceutical compositions for treating LPA-dependent or LPA-mediated diseases or conditions.

Abstract: Described herein is the DP2 anatgonist 2-(3-(2-((tert-butylthio)methyl)-4-(2,2-dimethyl-propionylamino)phenoxy)-4-methoxyphenyl)acetic acid, or a pharmaceutically acceptable salt thereof. Also described are methods of preparing the DP2 anatgonist, or a pharmaceutically acceptable salt thereof. Also described herein are pharmaceutical compositions suitable for administration to a mammal that include the DP2 anatgonist, or a pharmaceutically acceptable salt thereof, and methods of using such pharmaceutical compositions for treating respiratory diseases or conditions, allergic diseases or conditions, inflammatory diseases or conditions, as well as other prostaglandin D2-dependent or prostaglandin D2-mediated diseases or conditions.

Abstract: A pharmaceutically acceptable salt comprising 3-[3-tert-butylsulfanyl-1-[4-(6-ethoxy-pyridin-3-yl)-benzyl]-5-(5-methyl-pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionate as the anion and a cation selected from Na+, K+, Li+, Ca2+, NH4+, the protonated form of dicyclohexylamine, the protonated form of N-methyl-D-glucamine, the protonated form of tris(hydroxymethyl)methylamine, the protonated form of arginine, and the protonated form of lysine is disclosed, along with formulations and methods of using the same.

Abstract: Described herein is the DP2 antagonist [2?-(3-benzyl-1-ethyl-ureidomethyl)-6-methoxy-4?-trifluoromethyl-biphenyl-3-yl]-acetic acid, or a pharmaceutically acceptable salt thereof. Also described are methods of preparing the DP2 antagonist, or a pharmaceutically acceptable salt thereof. Also described herein are pharmaceutical compositions suitable for administration to a mammal that include the DP2 antagonist, or a pharmaceutically acceptable salt thereof, and methods of using such pharmaceutical compositions for treating respiratory diseases or conditions, allergic diseases or conditions, inflammatory diseases or conditions, as well as other prostaglandin D2-dependent or prostaglandin D2-mediated diseases or conditions.

Abstract: Described herein are methods for the synthesis of 3-[5-(pyridin-2-ylmethoxy)-3-(2-methyl-2-propylthio)-1-[4-(2-methoxypyridin-5-yl)benzyl]-indol-2-yl]-2,2-dimethyl-propionic acid, pharmaceutically acceptable salts, pharmaceutically acceptable solvates thereof. Also described are pharmaceutical compositions suitable for oral administration to a mammal that include, as well as methods of using such oral pharmaceutical compositions for treating respiratory conditions or diseases, as well as other leukotriene-dependent or leukotriene mediated conditions or diseases.